AUTL News and Press, Autolus Therapeutics plc From 04/20/21

LONDON, April 20, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received innovative licensing and access pathway (ILAP) designation from th...

LONDON, April 19, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that Dr Martin Murphy was appointed as non-executive chairman of its Board of Directors...

Immunocore is a "platform" pharmaceutical company looking to help naïve T cells recognize and kill their targets. Their technology involves soluble TCRs that recognize markers that indicate whether a cell is cancerous or infected with a virus. Their lead asset, tebentafusp, i...

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that management will participate in 1x1’s at investor conferences through April ...

Autolus Therapeutics (AUTL) has received PRIority MEdicines ((PRIME)) designation from the EMA for AUTO1,currently being investigated in the ongoing FELIX Phase 1b/2 study in relapsed / refractory adult B-Acute Lymphocytic Leukemia.PRIME, akin to Breakthrough Therapy status in the U.S., provi...

LONDON, April 01, 2021 (GLOBE NEWSWIRE) -- Autolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has received PRIority MEdicines (PRIME) designation from the European Medicines...

TCR2 Therapeutics (TCRR)  announces that it has signed a long-term, full-building lease with Alexandria Real Estate Equities (ARE) for an existing 85,000 square foot cell therapy manufacturing facility in Rockville, Maryland which is ready for Current Good Manufacturi...

Autolus Therapeutics (AUTL) shares jump 7% during premarket trading after the company announces plans to establish global commercial launch capacity in the UK, enabling the company to leverage the expertise and skill base of its employees in the region.The company argued t...

- Autolus to expand on existing operations in the UK for commercial supply of AUTO1 resulting in a less capital-intensive commercial infrastructure strategy - Mutual agreement to terminate lease for the manufacturing and office facility at 9950 Medical Center Drive, Rockville, MD, r...

The following slide deck was published by Autolus Therapeutics plc in conjunction with their 2020 Q4 earnings call. For further details see: Autolus Therapeutics plc 2020 Q4 - Results - Earnings Call Presentation